Equity Valuation Fresenius Medical Care AG & Co. KGaA

Detalhes bibliográficos
Autor(a) principal: Beissel, Philipp Alexander
Data de Publicação: 2023
Tipo de documento: Dissertação
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.14/42488
Resumo: This dissertation primarily aims to determine a target share price for Fresenius Medical Care, a Germany-based dialysis services and dialysis product provider. The company recently faced several macroeconomic headwinds, namely Covid-19, labour shortage, and inflation, lowering its profitability and thus decreasing the attractiveness for shareholders. In response, the company’s management issued a transformation program in 2020, which is expected to be completed by 2025. Main valuation methodologies applied are Discounted Cash Flows and Comparable Company Analysis, capturing the firm’s fundamental value with an infrastructure like business model, and reflecting the market perception of the industry’s prospects. Following the assumptions, the DCF reveals an intrinsic value of EUR 49.96 for the 31st of December 2022, representing an upside potential of 63% to the year-end share price of EUR 30.57. A limitation is certainly the yet-to-be-proven benefits related to the transformation program. Nevertheless, managements communicated goals appear to be realistic, given the company’s past financial track record with EBITDA margins between 19% and 22% (FY19A FY21A) and unparalleled market position. In line with the derived share price is the company’s current stock price (as of 31st of March 2023) of EUR 39.1, showcasing a 28% increase in the first quarter. Considering even the new share price, the upside potential is still 28%, leading to a strong buy recommendation. In addition, the trading level of comparable companies and conducted sensitivity analyses support this opinion.
id RCAP_89d09016743ebc3208e6664652f1bb7a
oai_identifier_str oai:repositorio.ucp.pt:10400.14/42488
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Equity Valuation Fresenius Medical Care AG & Co. KGaAEquity ValuationDialysisDiscounted cash flowsAvaliação de AcçõesDiáliseFluxo de caixa descontadosDomínio/Área Científica::Ciências Sociais::Economia e GestãoThis dissertation primarily aims to determine a target share price for Fresenius Medical Care, a Germany-based dialysis services and dialysis product provider. The company recently faced several macroeconomic headwinds, namely Covid-19, labour shortage, and inflation, lowering its profitability and thus decreasing the attractiveness for shareholders. In response, the company’s management issued a transformation program in 2020, which is expected to be completed by 2025. Main valuation methodologies applied are Discounted Cash Flows and Comparable Company Analysis, capturing the firm’s fundamental value with an infrastructure like business model, and reflecting the market perception of the industry’s prospects. Following the assumptions, the DCF reveals an intrinsic value of EUR 49.96 for the 31st of December 2022, representing an upside potential of 63% to the year-end share price of EUR 30.57. A limitation is certainly the yet-to-be-proven benefits related to the transformation program. Nevertheless, managements communicated goals appear to be realistic, given the company’s past financial track record with EBITDA margins between 19% and 22% (FY19A FY21A) and unparalleled market position. In line with the derived share price is the company’s current stock price (as of 31st of March 2023) of EUR 39.1, showcasing a 28% increase in the first quarter. Considering even the new share price, the upside potential is still 28%, leading to a strong buy recommendation. In addition, the trading level of comparable companies and conducted sensitivity analyses support this opinion.Esta dissertação tem como objetivo principal determinar um preço-alvo para as ações da Fresenius Medical Care, uma empresa sediada na Alemanha que fornece serviços de diálise e produtos para diálise. Desafios recentes, como Covid-19, escassez de mão de obra e inflação, afetaram sua lucratividade e atratividade para acionistas. A administração lançou um programa de transformação em 2020, previsto para ser concluído até 2025. As principais metodologias de valoração são Fluxos de Caixa Descontados e Análise de Empresas Comparáveis, refletindo a percepção do mercado e o valor fundamental da empresa. Com base nas suposições, o Fluxo de Caixa Descontado indica um valor intrínseco de EUR 49.96 em 31 de dezembro de 2022, potencializando uma valorização de 63% em relação ao preço de EUR 30.57 no final do ano. A limitação é a falta de comprovação dos benefícios do programa de transformação. No entanto, as metas comunicadas pela administração parecem realistas, considerando o histórico financeiro da empresa, com margens de EBITDA entre 19% e 22% (FY19A-FY21A) e uma posição de mercado excepcional. O preço atual das ações em 31 de março de 2023 é EUR 39.1, um aumento de 28% no primeiro trimestre. Mesmo com o novo preço das ações, há um potencial de valorização de 28%, indicando uma forte recomendação de compra. O nível de negociação de empresas comparáveis e as análises de sensibilidade corroboram essa opinião.Martins, José Carlos TudelaVeritati - Repositório Institucional da Universidade Católica PortuguesaBeissel, Philipp Alexander2023-06-292023-062024-05-31T00:00:00Z2023-06-29T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttp://hdl.handle.net/10400.14/42488TID:203329015enginfo:eu-repo/semantics/embargoedAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-09-26T01:44:03Zoai:repositorio.ucp.pt:10400.14/42488Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:30:56.497862Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Equity Valuation Fresenius Medical Care AG & Co. KGaA
title Equity Valuation Fresenius Medical Care AG & Co. KGaA
spellingShingle Equity Valuation Fresenius Medical Care AG & Co. KGaA
Beissel, Philipp Alexander
Equity Valuation
Dialysis
Discounted cash flows
Avaliação de Acções
Diálise
Fluxo de caixa descontados
Domínio/Área Científica::Ciências Sociais::Economia e Gestão
title_short Equity Valuation Fresenius Medical Care AG & Co. KGaA
title_full Equity Valuation Fresenius Medical Care AG & Co. KGaA
title_fullStr Equity Valuation Fresenius Medical Care AG & Co. KGaA
title_full_unstemmed Equity Valuation Fresenius Medical Care AG & Co. KGaA
title_sort Equity Valuation Fresenius Medical Care AG & Co. KGaA
author Beissel, Philipp Alexander
author_facet Beissel, Philipp Alexander
author_role author
dc.contributor.none.fl_str_mv Martins, José Carlos Tudela
Veritati - Repositório Institucional da Universidade Católica Portuguesa
dc.contributor.author.fl_str_mv Beissel, Philipp Alexander
dc.subject.por.fl_str_mv Equity Valuation
Dialysis
Discounted cash flows
Avaliação de Acções
Diálise
Fluxo de caixa descontados
Domínio/Área Científica::Ciências Sociais::Economia e Gestão
topic Equity Valuation
Dialysis
Discounted cash flows
Avaliação de Acções
Diálise
Fluxo de caixa descontados
Domínio/Área Científica::Ciências Sociais::Economia e Gestão
description This dissertation primarily aims to determine a target share price for Fresenius Medical Care, a Germany-based dialysis services and dialysis product provider. The company recently faced several macroeconomic headwinds, namely Covid-19, labour shortage, and inflation, lowering its profitability and thus decreasing the attractiveness for shareholders. In response, the company’s management issued a transformation program in 2020, which is expected to be completed by 2025. Main valuation methodologies applied are Discounted Cash Flows and Comparable Company Analysis, capturing the firm’s fundamental value with an infrastructure like business model, and reflecting the market perception of the industry’s prospects. Following the assumptions, the DCF reveals an intrinsic value of EUR 49.96 for the 31st of December 2022, representing an upside potential of 63% to the year-end share price of EUR 30.57. A limitation is certainly the yet-to-be-proven benefits related to the transformation program. Nevertheless, managements communicated goals appear to be realistic, given the company’s past financial track record with EBITDA margins between 19% and 22% (FY19A FY21A) and unparalleled market position. In line with the derived share price is the company’s current stock price (as of 31st of March 2023) of EUR 39.1, showcasing a 28% increase in the first quarter. Considering even the new share price, the upside potential is still 28%, leading to a strong buy recommendation. In addition, the trading level of comparable companies and conducted sensitivity analyses support this opinion.
publishDate 2023
dc.date.none.fl_str_mv 2023-06-29
2023-06
2023-06-29T00:00:00Z
2024-05-31T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.14/42488
TID:203329015
url http://hdl.handle.net/10400.14/42488
identifier_str_mv TID:203329015
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/embargoedAccess
eu_rights_str_mv embargoedAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799133577635430400